Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599).

ABSTRACT:

Purpose

Minzasolmin (UCB0599) is an orally administered, small molecule inhibitor of ASYN misfolding in development as a potential disease-modifying therapy for Parkinson's disease. Here we describe the preclinical development of a radiolabeled tracer and results from a phase 1 study using the tracer to investigate the brain distribution of minzasolmin.

Procedures

In the preclinical study, two radiolabeling positions were investigated on the S-enantiomer of minzasolmin (UCB2713): [¹¹C]methylamine UCB2713 ([¹¹C-N-CH₃]UCB2713) and [¹¹C]carbonyl UCB2713 ([¹¹C-CO]UCB2713). Male C57 black 6 mice (N = 10) received intravenous [¹¹C-N-CH₃]UCB2713; brain homogenates were assessed for radioactivity and plasma

SUBMITTER: Mercier J 

PROVIDER: S-EPMC10973027 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature